The studies reported here highlight an important property of anti-mesothelin mAb amatuximab as compared to anti-Lewis-Y mAb B3 for the Ag-mediated targeting of A431/H9 tumor overexpressing both a shed Ag, mesothelin, and a nonshed Ag, Lewis-Y, in a mouse model. This evidence concerns the gene MSLN and neoplasm.